Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis.

Cancer·2026
Same author

ZMYM2-FLT3 Fusion Gene: Implications for Chromosomal Instability and Proliferation in Myeloid/Lymphoid Neoplasms.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

Full-Length Immune Repertoire Reconstruction and Profiling at the Transcriptome Level Using Long-Read Sequencing.

Clinical chemistry·2024
Same author

Case report: Difficult diagnosis of <i>Mycobacterium tuberculosis</i> infection in patients after allogeneic hematopoietic stem cell transplantation: two case reports and a literature review.

Frontiers in oncology·2024
Same author

Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with <i>TP53</i> mutation.

Frontiers in immunology·2023
Same author

Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report.

Frontiers in medicine·2022

Related Experiment Video

Updated: May 4, 2026

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

8.2K

Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells.

Feng Gao1, Jia Liu2, Wan Wei Dong2

  • 1Department of Genetics, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China.

Oncology Reports
|December 17, 2013
PubMed
Summary

Arsenic trioxide (As2O3) reverses drug resistance in leukemia cells by inhibiting P-glycoprotein (P-gp) expression. This occurs via the NF-κB pathway, reducing MDR1 gene activity and enhancing treatment effectiveness.

More Related Videos

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
09:44

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia

Published on: September 5, 2019

6.6K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

6.6K

Related Experiment Videos

Last Updated: May 4, 2026

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays
11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

8.2K
Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia
09:44

Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia

Published on: September 5, 2019

6.6K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

6.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • P-glycoprotein (P-gp) mediates multidrug resistance in leukemia.
  • The mechanism by which arsenic trioxide (As2O3) inhibits P-gp expression is not fully understood.
  • Understanding this mechanism can lead to improved leukemia treatment strategies.

Purpose of the Study:

  • To investigate the effect of As2O3 on P-gp expression and regulation in leukemia cells.
  • To elucidate the molecular mechanism underlying As2O3-induced reversal of drug resistance.
  • To explore the role of the NF-κB pathway in this process.

Main Methods:

  • Electrophoretic mobility shift assay (EMSA) to assess p65 binding to the MDR1 promoter.
  • Western blotting to analyze the expression of p65, IκB, and phosphorylated IκB.
  • Luciferase reporter assay to measure NF-κB transcriptional activity.

Main Results:

  • As2O3 treatment reduced p65 and phosphorylated IκB expression while increasing IκB expression in K562/D cells.
  • EMSA confirmed p65 binding to the NF-κB site on the MDR1 gene.
  • As2O3 suppressed TNF-α-induced NF-κB activity, as measured by luciferase reporter gene expression.

Conclusions:

  • As2O3 reverses P-gp-mediated drug resistance in leukemia cells.
  • The mechanism involves the inhibition of the NF-κB signaling pathway.
  • As2O3 likely inhibits phosphorylase activity, preventing IκB phosphorylation, thus reducing NF-κB activation and MDR1 gene expression.